Evidence map›Paper›PMID 33810883›Full record

ArticleAmerican journal of otolaryngology

The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated.

Jerome R Lechien, Cosima C Hoch, Luigi A Vaira, Sven Saussez

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of otolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Jerome R LechienCOVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Human Anatomy and Experimental Oncology, Mons School of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium; Department of Otorhinolaryngology-Head and Neck Surgery, Foch Hospital, UVSQ, Paris Saclay University, Paris, France. Electronic address: Jerome.Lechien@umons.ac.be.
Cosima C HochCOVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Otorhinolaryngology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Luigi A VairaMaxillofacial Surgery Unit, University Hospital of Sassari, Sassari, Italy.
Sven SaussezCOVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France; Department of Human Anatomy and Experimental Oncology, Mons School of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Olfaction DisordersAnosmiaDysgeusiaFluticasoneHumansNasal SpraysSARS-CoV-2TriamcinoloneFluticasoneNasal SpraysTriamcinoloneCovidCovid-19FluticasoneSARS-CoV-2SmellSpray

Identifiers

PMID33810883
PMCPMC7987581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.